CME Presentations

Dyslipidemia, Diabetes, And Cardiovascular Risk


Presentations


Speakers

  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician; Medical Director, Continuing Medical Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Associate Professor of Medicine

    Om P. Ganda, MD, FACE, is associate professor of medicine at Harvard Medical School, and medical director of the Lipid Clinic and chair of the Clinical Oversight Committee at the Joslin Diabetes Center in Boston, Massachusetts. For more than 4 decades, Dr Ganda’s research has been focused in clinical diabetes, as a co-investigator in both the landmark Diabetes Control and Complications Trial (DCCT) and the Diabetes Prevention Program (DPP), which found that lifestyle changes and medication reduced progression to type 2 diabetes. He served on the AACE board of directors, was associate editor of Endocrine Practice, and is currently on the AACE-NE board of directors. He received his medical degree from SMS Medical College, University of Rajasthan in Jaipur, India.
  • Deepak Bhatt, MD

    Deepak Bhatt, MD

    Deepak Bhatt, MD

    Deepak L. Bhatt, MD, is executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School, and editor-in-chief of the Harvard Heart Letter. He specializes in cardiovascular medicine and interventional cardiology. Dr Bhatt is listed as a Thomson Reuters Highly Cited Researcher as the author of over 750 peer-reviewed publications. He is editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. Three projects Dr Bhatt helped lead were in the 2014 American Heart Association/American Stroke Association top ten advances in heart disease and stroke research. He is a trustee of the American College of Cardiology and was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar.

CME Information

Dyslipidemia, Diabetes, And Cardiovascular Risk: Clinical Strategies and Evolving Treatments


Joslin Diabetes Center Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Describe key treatment recommendations in accordance with current guidelines and recommendations from major expert groups, and how they would apply to type 2 diabetes treatment design that optimizes cardiovascular risk reduction
  • Initiate and advance treatments for diabetes and dyslipidemia using newer pharmacotherapies with evidence-based benefits in blunting cardiovascular risk, including GLP-1 receptor agonists, SGLT2 inhibitors, icosapent ethyl, and PCSK9 inhibitors
  • Overcome clinical barriers to the timely and effective therapeutic initiation of the latest antidiabetes and dyslipidemia lipid treatments that have demonstrated cardiovascular benefits

Acknowledgement

This activity is supported by an educational grant from Amarin Pharma Inc.

Tuition

Complimentary

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements

Live Internet Activities
Joslin Diabetes Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.
Enduring Material
Joslin Diabetes Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Internet Activity
Wednesday, June 3rd, from 2:00 – 3:00 PM ET
Enduring Material
The enduring material will be available from June 3, 2020 – December 3, 2020.

Intended Audience

Primary care providers, doctors of osteopathic medicine, diabetes specialists (such as endocrinologists and diabetologists), cardiologists, lipidologists, nurse practitioners, physician assistants and pharmacists. Other medical professionals, such certified diabetes educators, may also benefit from the education.

Method Of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 3 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Faculty Disclosures

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

The faculty and planning committee members for this program have disclosed the following:

Financial Disclosures

Faculty

  • Dr. Richard S. Beaser*†, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Dr. Om P. Ganda, MD, Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee, Joslin Diabetes Center, is a consultant for Amarin, and serves on the Ed Board at DynaMed Pro.

Planning Committee

  • Elizabeth del Nido, Senior Program Manager, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.
  • Carole Drexel, PhD, Medical Director, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.

Joslin CME Advisory Committee

  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
  • Alissa Segal, Pharm D, CDE, CDTC, FCCP, Clinical Pharmacist, Joslin Diabetes Center, has no relevant financial relationships.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* Also on the Planning Committee
† Also on the CME Advisory Committee

Contact Information

Please send content inquiries to: CME@Joslin.harvard.edu

For technical problems with the site or issues with your CME Certificate, please contact CardioCareLive or DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, CardioCareLive, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.